Disease · MONDO_0017844
Trials51
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 51
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01728805 | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL | Phase 3 | 372 | 2019-04-11 | Cutaneous T-Cell Lymphoma | MOGAMULIZUMAB, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02663518 | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors | Phase 1 | 249 | 2024-05-10 | Hematologic Malignancies, Solid Tumor | NIVOLUMAB, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00425555 | Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma | Phase 2 | 139 | 2021-08-16 | Cutaneous T-Cell Lymphoma | PANOBINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT03493451 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | Phase 2 | 77 | 2022-05-04 | Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK T Cell Lymphoma, Extranodal NK T Cell Lymphoma, Nasal, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory, Peripheral T-cell Lymphoma NOS, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Peripheral T-Cell Lymphoma Refractory, Anaplastic Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, ALK-negative Anaplastic Large Cell Lymphoma, ALK-Positive Anaplastic Large Cell Lymphoma, Cutaneous T-cell Lymphoma | TISLELIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00896493 | Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma | Phase 2 | 38 | 2023-05-11 | Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Cutaneous T-cell Lymphoma | CYCLOSPORINE | Its record names the disease | ClinicalTrials.gov |
| NCT01396070 | Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | Phase 2 | 36 | 2017-04-05 | Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma, Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome | BRENTUXIMAB VEDOTIN | Its record names the disease | ClinicalTrials.gov |
| NCT00466921 | Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome | Phase 2 | 33 | 2020-11-16 | Lymphoma | LENALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03063632 | Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma | Phase 2 | 28 | 2022-08-30 | Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma | INTERFERON GAMMA-1B, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00907738 | A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007) | Phase 2 | 27 | 2011-07-14 | Advanced Cancer | VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00744991 | A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma | Phase 2 | 25 | 2020-10-19 | Cutaneous T-Cell Lymphoma | ENZASTAURIN | Its record names the disease | ClinicalTrials.gov |
| NCT02243579 | Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome | Phase 2 | 24 | 2019-02-05 | Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7 | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00369629 | Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome | Phase 1 | 14 | 2018-10-09 | Lymphoma | GEMCITABINE, PEMETREXED | Its record names the disease | ClinicalTrials.gov |
| NCT04541017 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment | Phase 1/2 | 8 | 2025-10-16 | Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Sezary Syndrome, Refractory Mycosis Fungoides, Refractory Mycosis Fungoides and Sezary Syndrome, Refractory Sezary Syndrome, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 | MAGROLIMAB, MOGAMULIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00724061 | Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL | Not applicable | 7 | 2013-12-02 | Lymphoma | INTERFERON ALFA-2B, PSORALEN | Its record names the disease | ClinicalTrials.gov |
| NCT04185220 | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome | Phase 1 | 6 | 2021-12-14 | Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome, Mycosis Fungoides | INTERLEUKIN 15, RECOMBINANT NON-GLYCOSYLATED, MOGAMULIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00047060 | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | Phase 1/2 | 5 | 2020-02-24 | Mycosis Fungoides, Sezary Syndrome | ALEMTUZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT01226472 | Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 | Phase 2 | 1 | 2020-12-29 | Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma | MOGAMULIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03902184 | IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma | Phase 2 | 170 | Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome | LACUTAMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04858256 | Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | Phase 2 | 100 | T-Cell Neoplasm, Lymphoproliferative Disorders | PACRITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00127881 | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | Phase 3 | 76 | Mycosis Fungoides, Sezary Syndrome | ZANOLIMUMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0017844/trials